Observational studyAdvances in therapy2026

Real-World Clinical Outcomes and Treatment Patterns in Advanced/Metastatic EGFR-Mutant NSCLC After Progression on First-Line Osimertinib for French Patients.

Nicolas Girard et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.